CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Finasteride 5 mg tablets +1 moredrug
Likely dose
Finasteride 5 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835796
NCT00835796Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Non-Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 4, 2009·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating Finasteride 5 mg tablets and PROSCAR® 5mg tablets for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under non-fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 4, 2009
Enrollment StartJun 1, 2002
Primary CompletionJul 1, 2002
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.4 years ago

Interventions

Finasteride 5 mg tabletsdrug

1 x 5 mg, single dose fasting

PROSCAR® 5mg tabletsdrug

1 x 5 mg, single dose fasting